Department of Radiation Oncology, Haeundae Paik Hospital, Inje University School of Medicine, Busan 48108, Korea.
Department of Integrated Biological Science, Pusan National University, Busan 46241, Korea.
Int J Mol Sci. 2021 May 12;22(10):5111. doi: 10.3390/ijms22105111.
Although there are many patients with brain tumors worldwide, there are numerous difficulties in overcoming brain tumors. Among brain tumors, glioblastoma, with a 5-year survival rate of 5.1%, is the most malignant. In addition to surgical operations, chemotherapy and radiotherapy are generally performed, but the patients have very limited options. Temozolomide is the most commonly prescribed drug for patients with glioblastoma. However, it is difficult to completely remove the tumor with this drug alone. Therefore, it is necessary to discuss the potential of anticancer drugs, other than temozolomide, against glioblastomas. Since the discovery of cisplatin, platinum-based drugs have become one of the leading chemotherapeutic drugs. Although many studies have reported the efficacy of platinum-based anticancer drugs against various carcinomas, studies on their effectiveness against brain tumors are insufficient. In this review, we elucidated the anticancer effects and advantages of platinum-based drugs used in brain tumors. In addition, the cases and limitations of the clinical application of platinum-based drugs are summarized. As a solution to overcome these obstacles, we emphasized the potential of a novel approach to increase the effectiveness of platinum-based drugs.
尽管全球有许多脑瘤患者，但攻克脑瘤仍面临诸多困难。在脑瘤中，胶质母细胞瘤的 5 年生存率为 5.1%，最为恶性。除了手术，通常还会进行化疗和放疗，但患者的选择非常有限。替莫唑胺是胶质母细胞瘤患者最常开的药物，但仅用这种药物很难完全清除肿瘤。因此，有必要探讨替莫唑胺以外的抗癌药物对胶质母细胞瘤的潜在作用。自顺铂发现以来，铂类药物已成为最主要的化疗药物之一。尽管许多研究报告了铂类抗癌药物对各种癌的疗效，但对其治疗脑肿瘤的效果的研究还不够充分。在这篇综述中，我们阐明了铂类药物在脑肿瘤中的抗癌作用和优势。此外，还总结了铂类药物临床应用的病例和局限性。为了克服这些障碍，我们强调了增加铂类药物有效性的新方法的潜力。
